In this article, our co-founder and CEO, Chere Chapman, discusses how Goal Attainment Scaling (GAS) empowers patients to set personalized treatment goals that are monitored over time. This offers a richer understanding of treatment efficacy and explains how GAS supports the advancement of patient-centered clinical trials and the future of personalized medicine. It also includes real-world examples of GAS implementation with our partners Trend community and The Inchstone Project in rare diseases.

‍